Navigation Links
CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
Date:6/9/2010

DURHAM, N.C., June 9 -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study. Results of this study will allow the selection of doses for pivotal Phase III studies of lasmiditan in the acute treatment of migraine, scheduled to begin in fourth quarter this year.

"There is a high unmet need for novel migraine treatments that are effective and safe," said James F. White, Ph.D., President and Chief Executive Officer of CoLucid. "Currently available drugs have varying efficacy and side effects that limit their use in patients. Lasmiditan with its exciting new mechanism of action has the potential to address these patient needs."

In the recently completed double blind, randomized, placebo-controlled parallel group dose-ranging study conducted in five European countries, 391 patients treated a single migraine attack with one of four doses of lasmiditan or placebo. The Phase IIb study met its primary endpoint, showing a highly significant correlation between dose and headache relief at two hours. Individual doses showed significant benefit compared to the placebo from as early as 30 minutes after treatment. Lasmiditan also provided significant relief of other migraine symptoms, as measured in the study, including nausea, photophobia and phonophobia.

Dizziness and fatigue were the most common adverse events reported in the study. No clinically significant adverse effects were identified in either the laboratory parameters or electrocardiography (ECGs). Cardiovascular adverse events, including chest symptoms experienced with the current migraine medication group known as triptans, wer
'/>"/>

Contact: Shirley Chow
Shirley.chow@porternovelli.com
212-601-8308
Porter Novelli
Source:Eurekalert

Page: 1 2

Related biology news :

1. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
2. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
3. LaserCard Corporation Announces Expansion of Middle East Project
4. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
5. Balzan Foundation announces 2007 winners
6. The American Society of Plant Biologists announces 2007 awards
7. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
8. NIST announces 56 new awards for innovative technology research and development
9. Titanium Group Announces Contract With Haitong Securities
10. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
11. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
(Date:7/11/2014)... at the National Institute of Standards and Technology ... work more effectively, they often prove that necessity ... the case recently for M. Lorna De Leoz ... growing specialization of glycomics. Glycomics is the study ... that are attached to proteins and lipids and ...
(Date:7/11/2014)... 2014, Shenzhen, China Researchers from Salk Institute for ... first time evaluated the safety and reliability of ... developed a new method, TALEN-HDAdV, which could significantly ... cell (hiPSC). This study published online in ... foundation for stem cell-based gene therapy. , The ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... Health (NIMH), part of the National Institutes of Health, ... social behavior in humans--one of the most important but ... reported in Nature Neuroscience, published online on July 10, ... volunteers to those with a genetic abnormality, Williams Syndrome, ...
... Academy of Sciences (CAS) and the Danish Committee of ... release of pig genomic sequences. The released sequence data ... different domestic pig breeds from Europe and China. The ... genome sequencing effort, the Sino-Danish Pig Genome Project, started ...
... truckers and college students pulling all-nighters, appears to do ... is one of several in a new study that ... the modulation of sleep, wake, and arousal states. , ... colleagues at The Neurosciences Institute in San Diego. , ...
Cached Biology News:Scientists uncover new clues about brain function in human behavior 2Scientists uncover new clues about brain function in human behavior 3‘Blue Brain?project explores thought at molecular level 2
(Date:7/10/2014)... 2014 On July 9 Prime ... presented Russia,s first national "Industry" ... Company is developing a unique project called MabNext ... a number of innovative drugs based on monoclonal antibodies ... took place at the International Exhibition "Innoprom 2014" in ...
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
(Date:7/10/2014)... fight against terrorism with the creation of a sensor ... use of light and special glass fibres. , Published ... , the researchers describe a novel optical fibre sensor ... 6.3 ppm (parts per million). It requires an analysis ... detection has involved looking for metals that encase them ...
(Date:7/10/2014)... extremely challenging because there are many genetic variants that ... Now investigators reporting in the July 3rd issue of ... describe a strategy that may help reveal how such ... environmental exposures to affect the development of the nervous ... predispose individuals to schizophrenia. , The work takes ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2
... Robotic cars attracted attention last decade with a 100-mile driverless ... put up by the U.S. government. The past ... microrobots, miniaturized mobile machines designed to perform specific tasks. And ... some think the time has come for a microrobotics challenge. ...
... CASTRES, France , July 2, 2010 Olivier ... Pierre Fabre,Group starting September 1, 2010 . , ... Until now, Olivier Bohuon , 51, ... such, he ran the,group,s entire pharmaceutical activities from Chicago ( $22 ...
... ... progenitors into specific T cell lineages to the activity of a single gene encoding a ... for the development of blood cells lineages. , ... (PRWeb UK) July 1, 2010 -- A research team in Japan has ...
Cached Biology Technology:Thermal-powered, insect-like robot crawls into microrobot contenders' ring 2Thermal-powered, insect-like robot crawls into microrobot contenders' ring 3Olivier Bohuon Joins Pierre Fabre 2The Last Checkpoint to T Cell Fate 2